Noninvasive elastography‐based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis

The development of liver fibrosis markers in primary biliary cirrhosis (PBC) is needed to facilitate the assessment of its progression and the effectiveness of new therapies. Here, we investigated the potential usefulness of transient elastography (TE) in the noninvasive evaluation of liver fibrosis stage and disease progression in PBC. We performed, first, a prospective performance analysis of TE for the diagnosis of METAVIR fibrosis stages in a diagnostic cohort of 103 patients and, second, a retrospective longitudinal analysis of repeated examinations in a monitoring cohort of 150 patients followed‐up for up to 5 years. All patients were treated with ursodeoxycholic acid. Diagnostic thresholds of liver stiffness in discriminating fibrosis stages ≥F1, ≥F2, ≥F3, and =F4 were 7.1, 8.8, 10.7, and 16.9 kPa, respectively. TE showed high performance and was significantly superior to biochemical markers (e.g., aspartate aminotransferase [AST]/platelet ratio, FIB‐4, hyaluronic acid, AST/alanine aminotransferase ratio, and Mayo score) in diagnosing significant fibrosis, severe fibrosis, or cirrhosis. Analysis of the monitoring cohort data set using generalized linear models showed the following: (1) an overall progression rate of 0.48 ± 0.21 kPa/year (P = 0.02) and (2) no significant progression in patients with F0‐F1, F2, or F3 stages, but a significant increase (4.06 ± 0.72 kPa/year; P < 0.0001) in cirrhotic patients. A cut‐off value of 2.1 kPa/year was associated with an 8.4‐fold increased risk of liver decompensations, liver transplantations, or deaths (P < 0.0001, Cox regression analysis). Conclusion: TE is one of the best current surrogate markers of liver fibrosis in PBC. Over a 5‐year period, on‐treatment liver stiffness appears stable in most noncirrhotic PBC patients, whereas it significantly increases in patients with cirrhosis. Progression of liver stiffness in PBC is predictive of poor outcome. (HEPATOLOGY 2012;56:198–208)

[1]  O. Chazouilleres,et al.  Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. , 2011, Journal of hepatology.

[2]  V. de Lédinghen,et al.  FibroTest and Fibroscan performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate. , 2011, Clinics and research in hepatology and gastroenterology.

[3]  T. Arenovich,et al.  Baseline Ductopenia and Treatment Response Predict Long-Term Histological Progression in Primary Biliary Cirrhosis , 2010, The American Journal of Gastroenterology.

[4]  S. Friedman,et al.  Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis , 2010, Hepatology.

[5]  Y. Chrétien,et al.  Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone. , 2010, Gastroenterologie clinique et biologique.

[6]  V. de Lédinghen,et al.  Pitfalls of liver stiffness measurement: A 5‐year prospective study of 13,369 examinations , 2010, Hepatology.

[7]  K. V. van Erpecum,et al.  Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. , 2009, Gastroenterology.

[8]  T. Alempijevic,et al.  Biochemical markers for non-invasive assessment of disease stage in patients with primary biliary cirrhosis. , 2009, World journal of gastroenterology.

[9]  F. Marra,et al.  Elastography for the non-invasive assessment of liver disease: limitations and future developments , 2009, Gut.

[10]  A. West,et al.  Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay , 2008, Hepatology.

[11]  Y. Kondo,et al.  Transient elastography for measurement of liver stiffness measurement can detect early significant hepatic fibrosis in Japanese patients with viral and nonviral liver diseases , 2008, Journal of Gastroenterology.

[12]  Y. Chrétien,et al.  Biochemical response to ursodeoxycholic acid and long‐term prognosis in primary biliary cirrhosis , 2008, Hepatology.

[13]  M. Färkkilä,et al.  Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy , 2008, Liver international : official journal of the International Association for the Study of the Liver.

[14]  Eva Herrmann,et al.  Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. , 2008, Gastroenterology.

[15]  J. Gisbert,et al.  Transient elastography to assess hepatic fibrosis in primary biliary cirrhosis , 2007, Alimentary pharmacology & therapeutics.

[16]  E. Björnsson,et al.  The AST/ALT ratio as an indicator of cirrhosis in patients with PBC , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[17]  J. Montaner,et al.  Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.

[18]  M. Ziol,et al.  Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC , 2006, Hepatology.

[19]  J. Rodés,et al.  Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. , 2006, Gastroenterology.

[20]  Christos Christidis,et al.  Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C , 2005, Hepatology.

[21]  Y. Chrétien,et al.  Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA‐treated patients with primary biliary cirrhosis , 2004, Liver international : official journal of the International Association for the Study of the Liver.

[22]  J. Kalbfleisch,et al.  A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C , 2003, Hepatology.

[23]  F. Carrat,et al.  Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. , 2002, Gastroenterology.

[24]  O. Chazouilleres,et al.  Primary biliary cirrhosis–autoimmune hepatitis overlap syndrome: Clinical features and response to therapy , 1998, Hepatology.

[25]  P. Bedossa,et al.  An algorithm for the grading of activity in chronic hepatitis C , 1996, Hepatology.

[26]  R. Tibshirani,et al.  An Introduction to the Bootstrap , 1995 .

[27]  B. Balkau,et al.  Predictive factors in ursodeoxycholic acid‐treated patients with primary biliary Cirrhosis: Role of serum markers of connective tissue , 1994, Hepatology.

[28]  M. Vaubourdolle,et al.  Indocyanine green-sulfobromophthalein pharmacokinetics for diagnosing primary biliary cirrhosis and assessing histological severity. , 1991, Clinical chemistry.

[29]  P. Grambsch,et al.  Prognosis in primary biliary cirrhosis: Model for decision making , 1989, Hepatology.

[30]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[31]  E. Dickson,et al.  Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis) , 1978, Virchows Archiv A.

[32]  F. Lammert,et al.  EASL Clinical Practice Guidelines: management of cholestatic liver diseases. , 2009, Journal of hepatology.

[33]  M. Kenward,et al.  An Introduction to the Bootstrap , 2007 .

[34]  K. Lazaridis,et al.  Primary biliary cirrhosis , 1998, Springer Netherlands.